HK Stock Market Move | Luxshare Precision Industry (02475) rises nearly 3%; expects annual net profit attributable to shareholders to grow about 15%-20% year on year; related businesses expected to benefit from Apple's new product launch.
Luxshare Precision Industry (02475) rose nearly 3%, up 2.88% as of press time to HK$47.84, with a turnover of HK$31.196 million.
Luxshare Precision Industry (02475) rose nearly 3%, up 2.88% as of press time to HK$47.84, with turnover of HK$31.196 million.
On the news front, Luxshare Precision Industry recently issued an announcement that the group expects net profit attributable to shareholders of the listed company for 2026 to be RMB19.09 billion-RMB19.92 billion, up about 15%-20% year on year. Previously, Luxshare Precision Industry disclosed its third-quarter results. CICC noted that in 3Q26 alone, Luxshare achieved operating revenue of RMB110.507 billion, up 15% year on year; net profit attributable to parent was RMB5.214 billion, up 7% year on year, below the previously guided earnings range and below the bank's expectations.
Looking ahead, CICC believes that Apple recently launched the iPhone 18 Pro series, the Duo, and a number of new wearable and MacBook products. Luxshare has long participated in the supply of Apple's finished devices and core components, and the bank expects the new product launches to drive users to upgrade their devices, with Luxshare's related businesses benefiting. In addition, CICC expects Apple and overseas tech giants to launch multiple new hardware products in 2H26-2027. Luxshare has clear collaborative advantages in consumer electronics finished devices and components, and the bank expects the company to participate in the supply of related products.
Related Articles

HK Stock Market Move | SIMCERE PHARMA (02096) rises over 2% as it further enters into a collaboration with Lynk Pharmaceuticals on the selective JAK1 inhibitor zepuzetinib

HK Stock Market Move | SF INTRA-CITY (09699) rose more than 7% in morning trading; recently renewed a cooperation framework agreement with S.F. Holding, locking in a three-year long-term partnership.

AbbVie (ABBV.US) Expands UK Oxford R&D Facility, Betting on Innovation in Immunology, Neuroscience, and Oncology Drugs
HK Stock Market Move | SIMCERE PHARMA (02096) rises over 2% as it further enters into a collaboration with Lynk Pharmaceuticals on the selective JAK1 inhibitor zepuzetinib

HK Stock Market Move | SF INTRA-CITY (09699) rose more than 7% in morning trading; recently renewed a cooperation framework agreement with S.F. Holding, locking in a three-year long-term partnership.

AbbVie (ABBV.US) Expands UK Oxford R&D Facility, Betting on Innovation in Immunology, Neuroscience, and Oncology Drugs






